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miR-199a-3p inhibits cell proliferation and
induces apoptosis by targeting YAP1,
suppressing Jagged1-Notch signaling in
human hepatocellular carcinoma
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Abstract
Background: miR-199a-3p was significantly downregulated in the majority of human hepatocellular carcinoma (HCC)
tissues and HCC cell lines. Yes associated protein 1 (YAP1) was overexpressed in human HCC, which promoted HCC
development and progression by upregulating Jagged1 and activating the Notch pathway. We searched potential
targets of miR-199a-3p with DIANA, TargetScan and PicTar tools, and found that YAP1 is one of the potential targets.
Based on these findings, we speculated that miR-199a-3p might suppress HCC growth by targeting YAP1,
downregulating Jagged1 and suppressing the Notch pathway.
Results: We determined the expression of miR-199a-3p and YAP1 by quantitative Real-Time PCR (qRT-PCR) and
western blot assays, respectively, and found downregulation of miR-199a-3p and upregulation of YAP1 in HCC
cell lines. Cell proliferation and apoptosis assays showed that miR-199a-3p suppresses HCC cell proliferation and
promotes apoptosis, and knockdown of YAP1 has similar role. Furthermore, we verified that miR-199a-3p can
directly target YAP1. We further investigated and confirmed that miR-199a-3p and YAP1 regulate HCC cell
proliferation and apoptosis through Jagged1-Notch signaling.
Conclusion: miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit
HCC cell proliferation and promote apoptosis. These findings provide new insights into the mechanism by which
miR-199a-3p suppresses HCC cell proliferation and induces apoptosis.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumor in the word, particularly in East Asia
and South Africa [1, 2]. There are over 250,000 new HCC
cases and an estimated 600,000 HCC deaths each year [3].
Chronic hepatitis B Virus (HBV), hepatitis C Virus (HCV)
infection, and aflatoxin B1 exposure are the predominant
risk factors for the initiation of HCC [4]. Although great im-
provements in treatment options have been achieved in the
recent years, the prognosis of HCC patients remains very
poor, with a 5-year survival rate about 30 % [5]. The main
two reasons of the poor prognosis are the delay in diagnosis
of HCC and lack of effective treatment for advanced HCC
[6]. Undoubtedly, a better understanding of the underlying
molecular mechanisms of the initiation and development of
HCC will be conducive to identify novel biomarkers and de-
velop effective treatment strategies, which is very significant
to HCC patients. As the genesis and progress of other can-
cers, the initiation and development of HCC is also related
to the accumulated genetic alterations [7].
MicroRNAs (miRNAs), a class of short, non-coding
RNAs of about 19–25 nucleotides, post-transcriptionally
regulate gene expression by binding to partially comple-
mentary sites in the 3' untranslated regions (3’UTR) of
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targeted mRNAs, thereby causing translational repres-
sion or messenger RNA (mRNA) degradation [8]. miR-
NAs are involved in various biological processes,
including cell differentiation, proliferation, aging, apop-
tosis, migration, invasion, development and signal
transduction [9]. Increasing evidence shows that there
exist causal relationship between the deregulation of
miRNA expression and the initiation and development
of cancer, and miRNAs can play oncogenic or tumor
suppressive roles in human cancers depending on the
target genes [10]. In fact, many dysregulated miRNAs
have been reported to play important roles in the oc-
currence and progression of HCC, and miRNAs have
been suggested as potential biomarkers and novel
therapeutic targets for HCC [11, 12].
Recently, miR-199a-3p, a cancer-associated miRNA, is
widely reported to be deregulated in many malignant tu-
mors and its role in tumor development is controversial.
It can acts as either a tumor suppressor with downregu-
lated expression in some types of cancers, such as renal
cancer and bladder cancer, or an oncogene with upregu-
lated expression in gastric cancer and colorectal cancer
[13–15]. In HCC, miR-199a-3p has been reported to be
downregulated compared to corresponding nontumor
liver tissues [16–19]. We used DIANA, TargetScan and
and PicTar to perform target prediction analysis, and
found that Yes associated protein 1 (YAP1) is a potential
target of miR-199a-3p. YAP1 as an oncogene is highly
expressed in the various types of cancer, including HCC
[20–24]. Dong et al. [24] reported that liver-specific
overexpression of YAP1 leads to a greater than 5-fold
size enlargement which is reversible after cessation of
YAP1 expression. Recently, YAP1 has been reported to
promote HCC development and progression by upregu-
lating Jagged1 and activating the Notch pathway [25].
Therefore, we speculated that miR-199a-3p might regu-
late HCC cell proliferation and apoptosis in part by tar-
geting YAP1, downregulating Jagged1 and suppressing
the Notch pathway. In this study, we investigated
whether miR-199a-3p targets YAP1 to downregulate
Jagged1 and inhibit the Notch pathway, thereby regulat-
ing HCC cell proliferation and apoptosis.
Methods
Cell culture
Five human HCC cell lines (MHCC97H, Hep3B,
SMMC-7721, Huh7, and HepG2) and a normal liver cell
line (HL-7702) were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). Cells
were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA, USA) supplemented with
10 % fetal bovine serum (FBS, Invitrogen), 100 U/ml
penicillin and 100 mg/ml streptomycin at 37 °C with
5 % CO2 and 95 % humidity.
Cell treatment
Huh7 cells were transfected with miR-199a-3p mimic,
small interfering RNA for YAP1 (si-YAP1), pcDNA3.1
vectors containing the cDNA of YAP1 (pcDNA-YAP1),
pcDNA-Jagged1, si-Jagged1 and their respective controls
(Ribobio, Guangzhou, China) by using Lipofactamine
2000 (Invitrogen) according to the manufacturer’s in-
structions. To investigate whether introduction of miR-
199a-3p could increase HCC cell sensitivity to the drug
γ-secretase inhibitor n-[n-(3,5-difluorophenacetyl-l-ala-
nyl)]-s-phenylglycinet-butyl ester (DAPT; Calbiochem,
San Diego, CA, USA), Huh7 cells transfected with miR-
control or miR-199a-3p mimic were treated with DAPT
at a final concentration of 10 μM for 48 h.
MTT assay
Cell proliferation was measured using the 3-[4,5-di-
methyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium brom-
ide (MTT; Sigma-Aldrich, St. Louis, MO, USA) assay.
Briefly, cells were seeded into 96-well plates at a density
of 2 × 103 cells/well, and cultured for 48 h. Then 20 μl
of MTT (5 mg/ml) was added in each well followed by
incubation for 4 h at 37 °C. After removing the culture
medium, 150 μl/well of DMSO (Sigma-Aldrich) was
added to dissolve the precipitate. The absorbance was
measured at 570 nm by using a plate reader. Each ex-
periment was performed at least in triplicate.
Flow cytometry assay
Cell apoptosis was determined by using the Annexin V-
FITC apoptosis Detection Kit (BD Pharmingen, San
Diego, CA, USA) according to the manufacturer’s in-
structions. Cells were collected, washed and stained
using Annexin V-FITC and propidium iodide (PI). After
incubation for 15 min in darkness, the cells were exam-
ined by flow cytometry (BD Biosciences, San Jose, CA,
USA).
Caspase 3/7 activation assay
Caspase 3/7 activity was measured using Caspase-Glo 3/7
kit (Promega, Madison, WI, USA) according to the manu-
facturer’s instruction.
Real-time quantitative reverse transcription-PCR
(qRT-PCR)
Total RNA was extracted from the cells using TRIzol
(Invitrogen) according to the instructions of the
manufacturer. The cDNA was synthesized by using
SuperScript® III Reverse Transcriptase (Invitrogen),
and Real-time PCR amplifications were undertaken
using SYBR PrimeScript RT-PCR kit (Takara, Dalian,
China). GAPDH was used as an endogenous control
for mRNA. The miRNA was converted to cDNA by
using TaqMan MicroRNA Reverse Transcription Kit
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(Applied Biosystems, Foster City, CA, USA). The qRT-
PCR was performed using TaqMan Human MiRNA
Assay Kit (Applied Biosystems) with normalization to
U6 snRNA level. The primer sequences used were as
follows: miR-199a-3p, reverse transcription 5′-GTC
GTA TCC AGT GCA GGG TCC GAG GTA TTC
GCA CTG GAT ACG ACT AAC CA-3′, forward 5′-
GCG GCG GAC AGT AGT CTG CAC-3′ and reverse
5′-ATC CAG TGC AGG GTC CGA GG-3′; YAP1,
forward 5′-CCT GCG TAG CCA GTT ACC AA-3′
and reverse 5′-CCA TCT CAT CCA CAC TGT TC-
3′; GAPDH, forward 5′-GGC AAA TTC AAC GGC
ACA-3′ and reverse 5′-GTT AGT GGG GTC TCG
CTC CTG-3′; U6, forward 5′-CTC GCT TCG GCA
GCA CA-3′ and reverse 5′-AAC GCT TCA CGA
ATT TGC GT-3′.
Western blot
Protein samples were isolated from cell lysates and the
concentration of total protein was measured using BCA
Protein Assay Kit (Pierce, Rockford, IL, USA). Equal
amounts of samples (50 μg/lane) were separated by 10 %
SDS-PAGE and then transferred onto a polyvinylidene
difluoride membrane. After blocking in 5 % skimmed
milk, the membrane was incubated with the specific
antibody. The following primary antibodies were used:
YAP1 (Cell Signaling, Danvers, MA, USA), Jagged1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
Notch intracellular domain (NICD; Santa Cruz Biotech-
nology), Hes-1 (Abcam, Cambridge, UK), and β-actin
(Sigma-Aldrich). Goat anti-mouse/rabbit IgG antibody
conjugated to horseradish peroxidase (HRP) was used as
the secondary antibody (Gene Tech, Shanghai, China).
The blotted proteins were determined by using en-
hanced chemiluminescence regents (Thermo Scientific,
Waltham, MA, USA).
Luciferase reporter assay
The wild-type 3’UTR (3’UTR-WT) of YAP1 containing
the miR-199a-3p binding sites was obtained by PCR.
Mutant YAP1 3’UTR (3’UTR-MUT) which the mutations
occur in the conserved binding sites for miR-199a-3p, was
generated by using overlapping extension PCR. The frag-
ment of YAP1 3’UTR-WTand the mutant 3’UTR fragment
were inserted into XhoI/NotI-digested psiCHECK-2 vec-
tor (Promega) containing firefly and renilla luciferase re-
porter gene, respectively. The sequence of 3’UTR-WT of
YAP1 included the putative binding sites of miR-199a-3p,
while the sequence of 3’UTR-MUT of YAP1 not. Then
the psiCHECK-2 vectors with 3’UTR-WT or 3’UTR-MUT
regions of YAP1 were transfected into Huh7 cells contain-
ing miR-199a-3p mimics or miR-control, respectively. At
48 h after the transfection, cells were collected and lysed
for luciferase detection using Dual-Luciferase Reporter
System (Promega).
Statistical analysis
The SPSS 15.0 software (SPSS, Chicago, Illinois, USA)
was used for all statistical analyses. All data were
expressed as mean ± standard error (SE). Statistical ana-
lyses were determined by using two-tailed student’s t-test
or analysis of variance (ANOVA). P < 0.05 was consid-
ered statistically significant.
Results
miR-199a-3p was downregulated and YAP1 was
upregulated in HCC cell lines
miR-199a-3p expression was determined in five human
HCC cell lines (MHCC97H, Hep3B, Huh7, SMMC-7721
and HepG2) and a normal liver cell line (HL-7702) by
qRT-PCR. The results showed that the expression of
miR-199a-3p in HCC cell lines was very lower than that
in HL-7702 cells (Fig. 1a). We also detected the expres-
sion levels of YAP1 mRNA and protein in HCC cell lines
and HL-7702 cells using qRT-PCR and western blot, re-
spectively. When normalized to the normal liver cell
line, the expression of YAP1 mRNA and protein were
significantly increased in HCC cell lines (Fig. 1b and c).
These data indicated that miR-199a-3p was downregu-
lated and YAP1 was upregulated in HCC cell lines.
Overexpression of miR-199a-3p and knockdown of YAP1
inhibited proliferation and promoted apoptosis in HCC cells
In view of downregulation of miR-199a-3p and upregu-
lation of YAP1 in HCC cells, we further investigated
whether overexpression of miR-199a-3p and knock-
down of YAP1 had the same effects on proliferation
and apoptosis of HCC cells. We transfected Huh7 cells
with miR-199a-3p mimic and mimic control, respect-
ively. As measured by MTT assay, upregulation of miR-
199a-3p led to an obvious decrease of cell proliferation
rate in HCC cells (Fig. 2a). Flow cytometry assay
showed that apoptosis rate increased more than 5-fold
in Huh7 cells transfected with miR-199a-3p mimic,
compared to control group (Fig. 2b). Caspase 3/7 acti-
vation assay showed that Caspase 3/7 activity increased
more than 2-fold in the cells transfected with miR-
199a-3p mimic, compared to control group (Fig. 2c). In
addition, to understand the effects of YAP1 on HCC
cells, we transfected Huh7 cells with small interfering
RNA for YAP1 (si-YAP1) and si-control, and performed
MTT, flow cytometry and Caspase 3/7 activation assays.
As expected, YAP1 knockdown obviously suppressed
proliferation and induced apoptosis in Huh7 cells
(Fig. 2d–f ). Thus, upregulation of miR-199a-3p and
YAP1 deletion had the same effects on proliferation
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Fig. 1 The expression levels of miR-199a-3p and YAP1 in HCC cell lines. a Comparing differences in the expression levels of miR-199a-3p between
HCC cell lines and normal liver cell line HL-7702. b and c The expression levels of YAP1 mRNA and protein are determined by qRT-PCR and
western blot. *P < 0.05, **P < 0.01 and ***P < 0.001
Fig. 2 Overexpression of miR-199a-3p and knockdown of YAP1 inhibit proliferation and induce apoptosis in HCC cells. a and d The effects
of overexpression of miR-199a-3p and knockdown of YAP1 on Huh7 cell proliferation are detected by MTT assay. b and e The effects of
overexpression of miR-199a-3p and knockdown of YAP1 on Huh7 cell apoptosis are assessed by flow cytometry assay. c and f Caspase
3/7 activity is measured in Huh7 cells transfected with miR-control, miR-199a-3p mimic, si-control or si-YAP1. *P < 0.05, **P < 0.01
and ***P < 0.001
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and apoptosis of HCC cells, which inhibited HCC cell
proliferation and promoted apoptosis.
YAP1 was identified as a functional target of miR-199a-3p
To further investigate the molecular mechanism by
which miR-199a-3p inhibited proliferation and promoted
apoptosis in HCC cells, publicly available databases
(DIANA, TargetScan and PicTar) were searched for the
targets of miR-199a-3p, and YAP1 was a potential target
of miR-199a-3p based on the putative target sequence at
249–255 base pairs of the YAP1 3’UTR (Fig. 3a). We
also performed Gene Ontology (GO) analysis (data not
shown), and found YAP1 is involved in various biological
processes, such as cellular macromolecule metabolic
process, developmental process, regulation of signaling,
cell proliferation and apoptosis. Then luciferase reporter
assay was performed on Huh7 cells to identify whether
miR-199a-3p directly interacted with the 3’UTR of YAP1
mRNA. The results showed that overexpression of miR-
199a-3p reduced the luciferase activity of the luciferase
reporter containing wild type 3’UTR of YAP1 but not
mutant reporter (3’UTR-MUT) vector (the sequences of
YAP1 3’UTR-WT/MUT shown in Fig. 3a), which indi-
cated that YAP1 is indeed a direct target of miR-199a-3p
Fig. 3 YAP1 is a functional target of miR-199a-3p in HCC cells. a Bioinformatics-based target prediction analysis represents that YAP1 is a potential
target of miR-199a-3p and the putative binding sequence is in the 3’-UTR of YAP1 mRNA. b Luciferase reporter assay shows that the luciferase
activity in cells containing miR-199a-3p and 3’UTR-WT of YAP1 is markedly decreased compared with the negative control and 3’UTR-MUT groups.
c and d qRT-PCR and western blot analyses shows that miR-199a-3p overexpression signigficantly downregulates mRNA and protein levels of
YAP1.e–g MTT, flow cytometry and Caspase 3/7 activation assays show that the upregulation of YAP1 partially reverses miR-199a-3p’s effect on
the proliferation and apoptosis of Huh7 cells. *P < 0.05, **P < 0.01 and ***P < 0.001
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(Fig. 3b). Furthermore, to confirm that miR-199a-3p can
regulate YAP1 expression, qRT-PCR and western blot
assays were performed to determine the expression of
YAP1 mRNA and protein in response to the alteration
of miR-199a-3p expression in Huh7 cells. Results from
qRT-PCR revealed that miR-199a-3p markedly reduced
the expression of YAP1 mRNA compared with the con-
trol group (Fig. 3c). Western blot assay showed an obvi-
ous reduction of YAP1 expression after overexpression
of miR-199a-3p (Fig. 3d). Proliferation (MTT) and apop-
tosis (flow cytometry and Caspase 3/7 activation) assays
showed that the upregulation of YAP1 partially reversed
miR-199a-3p's effect on the proliferation and apoptosis
of Huh7 cells (Fig. 3e–g). While overexpression of YAP1
fails to fully restore miR-199a-3p's effect on proliferation
and apoptosis, probably due to a sufficiently high en-
dogenous level of YAP1 already existing in Huh7 cells.
Taken together, our data strongly suggest that YAP1 is a
target of miR-199a-3p, and miR-199a-3p regulates prolif-
eration and apoptosis of HCC cells, at least partially, by
directly targeting YAP1.
Jagged1 relieved the effects of upregulation of miR-199a-
3p and inhibition of YAP1 on HCC cells
To investigate whether miR-199a-3p targets YAP1, and
downregulates Jagged1 to inhibit proliferation and pro-
mote apoptosis of HCC cells, we firstly upregulated
miR-199a-3p and downregulated YAP1 by transfecting
miR-199a-3p mimics, si-YAP1 and their respective con-
trols into Huh7 cells, respectively, and observed the ex-
pression of Jagged1 protein. Western blot analysis
presented that efficient upregulation of miR-199a-3p and
inhibition of YAP1 reduced expression of Jagged1 pro-
tein (Fig. 4a and b). In view the inhibitory effects of
miR-199a-3p and YAP1 knockdown on Jagged1 expres-
sion in Huh7 cells, we further investigated whether
miR-199a-3p and YAP1 silencing had the same effects
on the function of Jagged1. First, we transfected Huh7
cells with following reagents: miR-control, miR-199a-3p
mimic, miR-199a-3p mimic + pcDNA-NC (miR + pcDNA-
NC), miR + pcDNA-Jagged1, si-control, si-YAP1, si-YAP1
+ pcDNA-NC, si-YAP1 + pcDNA-Jagged1. Wetern blot
assays confirmed that transfection was successful for all
combinations (Fig. 4c and g). Then we performed pro-
liferation and apoptosis assay. Proliferation assay
showed that high expression of miR-199a-3p and
knockdown of YAP1 significantly reduced proliferation
in Huh7 cells at 48 h, while the proliferation rate in
pcDNA-Jagged1 co-transfected cells was obviously in-
creased (Fig. 4d and h). The examination of apoptosis
showed that apoptosis was induced in Huh7 cells with
miR-199a-3p overexpression or YAP1 deletion, in-
versely, less apoptosis was observed after cells were co-
transfected with pcDNA-Jagged1 vector (Fig. 4e, f, i
and j). These data indicated that upregulation of miR-
199a-3p and inhibition of YAP1 suppressed cell prolif-
eration and promoted apoptosis, whereas, Jagged1
could relieve these effects on HCC cells.
miR-199a-3p and YAP1 regulated proliferation and
apoptosis of HCC cells through Jagged1-Notch signaling
Jagged1 as a Notch ligand is an important component
of the Notch pathway. We further determined the ef-
fects of miR-199a-3p and YAP1 on the Notch signaling.
Western blot analysis showed that miR-199a-3p overex-
pression and YAP1 knockdown in Huh7 cells reduced
expression of Notch intracellular domain (NICD) and
the Notch target gene Hes-1, indicating diminished the
Notch pathway activity (Fig. 5a and b). In addition, we
investigated whether introduction of miR-199a-3p could
increase the drug sensitivity of DAPT-treated HCC cells.
DAPT, a γ-secretase inhibitor, can block the Notch signal-
ing. The data suggested that Huh7 cells treated by miR-
199a-3p mimic and DAPT had an obviously lower cell
proliferation rate and a significantly higher apoptosis rate
than the control cells treated by miR-control and DAPT,
which indicated that miR-199a-3p could increase HCC
cell sensitivity to DAPT (Fig. 5c–e). Taken together, our
results, for the first time, illustrated the miR-199a-3p-
YAP1-Jagged1-Notch signaling in HCC, in which miR-
199a-3p targets YAP1 and regulates the Jagged1-Notch
signaling to inhibit the tumorigenesis of HCC. This regu-
latory network may help to lead a better understanding of
HCC initiation and progression and contribute to the
miRNA-targeted therapy for this deadly disease.
Discussion
Primary liver cancer is the third leading cause of cancer-
related death in the world, and HCC is the most fre-
quent subtype, which has a complex pathogenesis [26].
Although the major risk factors are known, therapeutic
options in HCC patients remain limited, which less than
30 % of newly diagnosed HCC patients are eligible for
currently curative therapies such as liver transplantation,
resection or local ablation [27]. This is in part because
of our incomplete understanding of the cellular and mo-
lecular mechanisms of HCC initiation and progression.
Therefore, deepening understanding of the cellular and
molecular mechanisms influencing HCC development is
very essential. With an increasing number of high-
throughput data from different genomic levels being
generated, the possibility of integrating these data pro-
vides us an excellent opportunity to identify critical gen-
etic and epigenetic alterations in HCC. Among them,
miRNAs and their targets may represent potential novel
biomarkers or therapeutic targets for HCC. Many stud-
ies have demonstrated that miRNAs modulate the ex-
pression of tumor suppressor or oncogene, which
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suggests a new mechanism involved in the initiation and
progression of HCC.
miR-199a-3p was of interest to us because it was
downregulated in several HCC studies [18, 28]. miR-
199a-3p was also decreased in alcohol induced steato-
hepatitis, a known precursor to HCC [29]. Restoration
of miR-199a-3p decreased HCC cell invasion and pro-
liferation [30]. By bioinformatics-based target predic-
tion analysis with DIANA, TargetScan and PicTar tools,
we found that CD44, PAK4 and YAP1 were potential
targets of miR-199a-3p. Henry et al. [19] reported that
miR-199a-3p represses proliferation of CD44 positive
HCC cell lines by targeting CD44. Hou et al. [16] re-
ported that miR-199a/b-3p target PAK4 to inhibit the
growth of HCC through suppressing PAK4/Raf/MEK/
ERK pathway. YAP1 was upregulated in HCC tissues
and cells, and promoted HCC development and
progression [24]. In addition, recently miR-497 and
miR-506 were reported to inhibit cell proliferation and
induce apoptosis by targeting YAP1 in HCC [31, 32].
Therefore, we speculated that miR-199a-3p might target
YAP1 to regulate HCC cell proliferation and apoptosis.
Our experimental results confirmed our speculation that
downregulation of miR-199a-3p and upregulation of
Fig. 4 The Notch ligand Jagged1 is a functional YAP1 target. a and b High expression of miR-199a-3p and YAP1 silencing significantly inhibit
protein level of Jagged1. c and g Wetern blot assays confirm that transfection is successful for all combinations. d–f Overexpression of miR-199a-3p
reduces cell proliferation and induces apoptosis, however, Jagged1 relieves these effects in Huh7 cells. h–j si-YAP1 significantly inhibits cell proliferation
and induces apoptosis in Huh7 cells, while Jagged1 reverses these effects. *P < 0.05, **P < 0.01 and ***P < 0.001
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YAP1 existed in HCC cells, and miR-199a-3p inhibited
cell proliferation and induced apoptosis partly by targeting
YAP1.
The Notch pathway is an evolutionarily conserved sig-
naling, which includes Notch ligands, receptors, target
transcription factors, and negative and positive modi-
fiers. As an important signaling pathway, Notch pathway
not only participates in embryonic development and cell
fate determination, but also plays an important role in
cancer [33]. However, the role of Notch signaling in
tumorigenesis is controversial. For instance, the Notch
pathway is aberrantly activated in some malignant tu-
mors, such as colorectal, breast and lung carcinomas,
and play the tumor-facilitative role, which the inappro-
priate activation of Notch in these tumors is caused by a
dysbalance between Notch ligands, such as Jagged1 and
inhibitors [34, 35]. While activation of the Notch path-
way has also been reported to suppress tumor growth,
including neural crest tumors and skin cancer [36, 37].
The Notch pathway seems to act as a tumor suppres-
sor or an oncogene, depending on the tissue type. For
the role of the Notch pathway in HCC, many studies
have demonstrated that the Notch signaling pathway
is activated, and plays the tumor-facilitative role in
HCC [38, 39]. Recently, Jagged1-Notch signaling was
reported to be activated by YAP1, thereby promoting
HCC development and progression [25]. Based on
these findings, we speculated that miR-199a-3p might
regulate HCC cell proliferation and apoptosis in part
by targeting YAP1 and suppressing Jagged1-Notch sig-
naling. Our experiments also confirmed our specula-
tion that miR-199a-3p inhibits HCC cell proliferation
and induces apoptosis in part by targeting YAP1 and
suppressing Jagged1-Notch signaling.
Conclusions
In summary, our results, for the first time, illustrated the
miR-199a-3p-YAP1-Jagged1-Notch signaling in HCC, in
which miR-199a-3p targets YAP1 and represses the
Jagged1-Notch signaling to inhibit the tumorigenesis of
HCC. This regulatory network contributes to a better
understanding of HCC initiation and progression and
the miRNA-targeted therapy for this deadly disease.
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